Alzheimer’s disease remains one of the largest challenges for the global ageing population. In this article, Victoria Rees, Editor of Drug Target Review, reviews some of the latest research, highlighting how progress has been made in understanding tau as well as how to potentially target this protein as a therapeutic strategy against…
List view / Grid view
Researchers have successfully characterised a part of the brain that shows the earliest accumulation of tau protein, an important biomarker for the development of Alzheimer's disease.
Researchers have designed a COVID-19 vaccine to be less sensitive to mutations and equipped for future strains.
Researchers have linked resistance to kidney cancer treatment to low mitochondrial content in cancer cells
When the researchers increased the mitochondrial content with an inhibitor, the cancer cells responded to the treatment.
Scientists from Karolinska Institutet have found mechanisms associated with a particular diabetes drug that can also help to protect against Alzheimer’s disease.
New research from the Karolinska Institutet shows that RNA molecules have a much broader function in the development of cancer.
Research has shown that memory T cells formed following SARS-CoV-2 infection or mRNA vaccination respond to the Omicron variant.
The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
A study has shown that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared with healthy individuals.
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
New research has shown that MAIT cells are strongly activated in people with moderate to severe COVID-19 disease.
Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.